Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 18 Jul 2022
Celcuity announces FDA breakthrough therapy designation for gedatolisib for treatment of HR positive, HER2 negative metastatic breast cancer
18 July 2022 - Celcuity today announced that the U.S. FDA has granted gedatolisib breakthrough therapy designation for the treatment of ...
Posted by Michael Wonder on 18 Jul 2022
Mycovia Pharmaceuticals announces U.S. availability of Vivjoa (oteseconazole) capsules, the first and only FDA approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection)
18 July 2022 - Vivjoa is now available in a network of partner pharmacies that includes mail order and local pickup ...
Posted by Michael Wonder on 18 Jul 2022
Aussies could get omicron targeted jab earlier than most
18 July 2022 - Australia could become one of the first countries in the world to administer an omicron-specific vaccine, ...
Posted by Michael Wonder on 18 Jul 2022
More children now eligible for cystic fibrosis drug
18 July 2022 - Effective today, the Province will pay for the cystic fibrosis drug Trikafta for children aged six to ...
Posted by Michael Wonder on 18 Jul 2022
A price that isn’t soaring: prescription drugs
18 July 2022 - Prescription medicine prices rose 0.1% in June, and 2.5% in the last year. ...
Posted by Michael Wonder on 18 Jul 2022
DiRx launches groundbreaking annual savings plan: unlimited prescriptions and refills for more than 1,000 generic medications for one annual fee
18 July 2022 - DiRx, an online pharmacy eliminating barriers to medicine affordability and accessibility, today launched its two-tiered Annual ...
Posted by Michael Wonder on 18 Jul 2022
Acadia Pharmaceuticals submits new drug application to the U.S. FDA for trofinetide for the treatment of Rett syndrome
18 July 2022 - Acadia Pharmaceuticals today announced that the company has submitted a new drug application to the U.S. FDA ...
Posted by Michael Wonder on 18 Jul 2022
Velmanase alfa for the treatment of alfa mannosidosis
15 July 2022 - The Department of Health and Social Care has asked NICE to produce guidance on using velmanase alfa ...
Posted by Michael Wonder on 18 Jul 2022
Renuvion cleared by FDA for neck laxity procedures offering patients a minimally invasive option to eliminate sagging neck
18 July 2022 - Exclusive Apyx Medical device delivers state of the art plasma energy to improve appearance of loose ...
Posted by Michael Wonder on 18 Jul 2022
Azurity Pharmaceuticals announces FDA approval of Zonisade (zonisamide oral suspension)
18 July 2022 - The first and only FDA approved zonisamide oral liquid formulation. ...
Posted by Michael Wonder on 18 Jul 2022
EMA validates marketing authorisation application for trastuzumab duocarmazine (SYD985) in HER2 positive metastatic breast cancer
18 July 2022 - Submission follows positive results of Phase 3 TULIP trial. ...
Posted by Michael Wonder on 18 Jul 2022
Everest Medicines announces European Commission grants approval of Kinpeygo for adults with primary IgA nephropathy to our partner Calliditas Therapeutics
17 July 2022 - Kinpeygo (developed under the name Nefecon) is the first and only EMA approved treatment for IgAN. ...
Posted by Michael Wonder on 18 Jul 2022
Relief Therapeutics announces that its collaboration partner has resubmitted the ACER-001 (sodium phenylbutyrate) new drug application to the FDA for the treatment of urea cycle disorders
18 July 2022 - Relief Therapeutics today announced that its collaboration partner, Acer Therapeutics for ACER-001 (sodium phenylbutyrate) for oral ...
Posted by Michael Wonder on 18 Jul 2022
AbbVie submits marketing authorisation application to EMA for atogepant for the preventive treatment of migraine
18 July 2022 - The submission is based on two pivotal Phase 3 studies evaluating atogepant in adult patients with episodic ...
Posted by Michael Wonder on 17 Jul 2022
'Government excessively controls drug prices, not recognising novel drugs' value'
15 July 2022 - The Government is wielding excessive power to lower drug prices without recognising the values of innovative ...